Blockade of miR-140-3p prevents functional deterioration in afterload-enhanced engineered heart tissue

Scientific Reports
Tessa R WernerMarc N Hirt

Abstract

Afterload enhancement (AE) of rat engineered heart tissue (EHT) in vitro leads to a multitude of changes that in vivo are referred to as pathological cardiac hypertrophy: e.g., cardiomyocyte hypertrophy, contractile dysfunction, reactivation of fetal genes and fibrotic changes. Moreover AE induced the upregulation of 22 abundantly expressed microRNAs. Here, we aimed at evaluating the functional effect of inhibiting 7 promising microRNAs (miR-21-5p, miR-146b-5p, miR-31a-5p, miR-322-5p, miR-450a-5p, miR-140-3p and miR-132-3p) in a small-range screen. Singular transfection of locked nucleic acid (LNA)-based anti-miRs at 100 nM (before the one week AE-procedure) led to a powerful reduction of the targeted microRNAs. Pretreatment with anti-miR-146b-5p, anti-miR-322-5p or anti-miR-450a-5p did not alter the AE-induced contractile decline, while anti-miR-31a-5p-pretreatment even worsened it. Anti-miR-21-5p and anti-miR-132-3p partially attenuated the AE-effect, confirming previous reports. LNA-anti-miR against miR-140-3p, a microRNA recently identified as a prognostic biomarker of cardiovascular disease, also attenuated the AE-effect. To simplify future in vitro experiments and to create an inhibitor for in vivo applications, we design...Continue Reading

References

Jan 5, 2002·The New England Journal of Medicine·J N CohnUNKNOWN Valsartan Heart Failure Trial Investigators
Aug 18, 2004·Biochemical and Biophysical Research Communications·Doubun HayashiIssei Komuro
Nov 30, 2004·Clinical and Experimental Pharmacology & Physiology·Robyn L Woods
Jul 4, 2007·Circulation·Thomas ThumJohann Bauersachs
Jan 13, 2009·Nature Cell Biology·Qinghang LiuJeffery D Molkentin
May 8, 2010·Circulation Research·Arne HansenThomas Eschenhagen
Jul 21, 2010·The Journal of Experimental Medicine·Gang LiuEdward Abraham
Feb 3, 2011·The Journal of Clinical Investigation·Thomas ThumStefan Engelhardt
Sep 21, 2011·Biochemistry·Richard OwczarzyAndrey V Tataurov
Sep 26, 2012·The Journal of Physiological Sciences : JPS·Xiaoying JiangJuanli Wang
Oct 27, 2012·Basic Research in Cardiology·Marc N HirtThomas Eschenhagen
Jul 16, 2013·Biochimica Et Biophysica Acta·Irina A Sergeeva, Vincent M Christoffels
Nov 28, 2013·Nucleic Acids Research·Ana Kozomara, Sam Griffiths-Jones
Sep 2, 2014·The New England Journal of Medicine·John J V McMurrayUNKNOWN PARADIGM-HF Investigators and Committees
Nov 8, 2014·Nucleic Acids Research·Nathan Wong, Xiaowei Wang
Jan 31, 2015·Journal of Molecular and Cellular Cardiology·Marc N HirtThomas Eschenhagen
Nov 11, 2015·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Marc N HirtThomas Eschenhagen
Nov 19, 2015·European Heart Journal·John J J V McMurray
May 19, 2016·Journal of Molecular and Cellular Cardiology·Anja ByeUlrik Wisløff
Apr 22, 2017·European Heart Journal·Wolfgang PollerUlf Landmesser
May 12, 2017·Nature Protocols·Kaja BreckwoldtArne Hansen
Sep 4, 2017·Journal of Molecular and Cellular Cardiology·Eliana C MartinezArthur Mark Richards
Oct 13, 2017·Nature Reviews. Cardiology·Charlotte Andersson, Ramachandran S Vasan
Sep 2, 2018·Journal of Cardiovascular Translational Research·Yongqin LiYihua Bei

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection
RNA-seq
antisense oligonucleotides
RNA

Software Mentioned

ImageJ
miRDB
CTMV
GraphPad Prism
Exiqon

Related Concepts

Related Feeds

Cardiac Regeneration

Cardiac regeneration enables the repair of irreversibly damaged heart tissue using cutting-edge science, including stem cell and cell-free therapy. Discover the latest research on cardiac regeneration here.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.